Uncategorized

ProLung Announces the Appointment of Dr. Robin L. Smith to its Board of Directors

Salt Lake City, Utah, February 16, 2017 – ProLung, a predictive analytics and risk stratification company that has developed a novel, cost effective, and non-invasive test to identify cancerous and noncancerous lung nodules, announced today that Robin L. Smith, MD, MBA, has joined the Company’s Board of Directors.

“ProLung is pleased to have the guidance of Dr. Smith as we complete our pivotal trial enrollment and begin positioning the company toward commercialization,” stated Steven Eror, CEO and founder of ProLung. “Her extensive experience as a thought leader in the healthcare space will be of great benefit to our shareholders and patients as we reach significant milestones,” added Todd Morgan, Chairman of the Board.

“I am pleased to be joining ProLung at this exciting moment,” stated Dr. Smith. “I believe there is an urgent need in the practice of pulmonology to assist practitioners with an objective, non-radiating, and non-invasive tool. ProLung’s technology is already approved in Europe and is currently saving lives.”

Dr. Smith serves as Chairman of the Board for MYnd Analytics, is a director of Rockwell Medical and serves as a director of Bioxcel Corporation. She is Chairman of the Board of the Cura Foundation and Stem for Life Foundation. She also serves on the international board of Stanford Health and is Vice President of the STOQ Foundation of the Vatican dedicated to the dialogue between science and faith. Dr. Smith earned her M.D. from Yale University and M.B.A. from the Wharton School of Business.

About ProLung

ProLung’s mission is to make a difference in time for lung cancer patients. ProLung is a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer. The Company develops, tests, and commercializes solutions which may […]

By |16 February 2017|Uncategorized|Comments Off on ProLung Announces the Appointment of Dr. Robin L. Smith to its Board of Directors|

Shareholder Update Letter

January 15, 2017

 

Happy New Year from ProLung!

2016 has been a spectacular year.

To achieve our research goals more rapidly, we assembled the most extensive team of clinical investigators of lung cancer in pulmonology.

This speeds the clinical evaluation required for FDA market approval, sets the stage for rapid commercial rollout, insurance reimbursement and commercial growth. The quality of the physician investigators in the US and in Europe is beyond what we could have imagined at this point last year.  These clinics, now active in ProLung’s pivotal trial, have choices in what to research.  As shareholders, we are deeply grateful for each clinic’s commitment.  Today, lung cancer remains the leading cause of cancer death for men and women.  With the help from these champion clinicians, a better pathway is just around the corner.   2016 brought the golden age of pulmonology.  Here are the clinics that are bringing ProLung and their patients into that age by participating in ProLung research or offering the ProLung test to patients (Europe):

Azienda Ospedaliera Universitaria San Martino di Genova (pulmonology)
Azienda Ospedaliera Universitaria San Martino di Genova (thoracic surgery)
Azienda Ospedaliero Universitaria Maggiore della Carità di Novara
Azienda Ospedaliero Universitaria Careggi
Chicago Chest Center Interventional Pulmonology and Thoracic Disease
Greater Baltimore Medical Center
Harvard University at Beth Israel Deaconess Hospital
Henry Ford Hospital
Huntsman Cancer Institute at the University of Utah
Intermountain Healthcare
Johns Hopkins School of Medicine
Loyola University, Providence Health Center
Lungenklinik Löwenstein
M D Anderson Cancer Center
Medical University of South Carolina
Northwestern Memorial Hospital
Stanford Healthcare
Università Politecnica della Marche
Universitätsspital Basel
University of California at Los Angeles (pulmonology)
University of California at Los Angeles (radiology)
University of California at San Diego
University of Geneva
University of Minnesota […]

By |15 January 2017|Uncategorized|Comments Off on Shareholder Update Letter|

Gregory C. Simon Meeting

Steven C. Eror, President and CEO, meets with Gregory C. Simon, White House Cancer Moonshot Task Force, Executive Director in the Office of the Vice President.

By |10 December 2016|Uncategorized|Comments Off on Gregory C. Simon Meeting|

ProLung CEO Interviewed at the BIO Investor Forum

San Francisco, California, Wednesday October 19, 2016

 

By |2 November 2016|Uncategorized|Comments Off on ProLung CEO Interviewed at the BIO Investor Forum|

ProLung Interviewed by National Healthcare Reporter

 

12/10/2016

   ProLungDX seeks funds for cancer test; sees eventual IPO – CEO 
   Proprietary Intelligence

Story

ProLungDX, a maker of lung cancer detection devices, is looking to raise USD 5.25m from high net worth investors for US commercial development in advance of an expected initial public offering or trade sale, according to CEO Steven Eror.
The Salt Lake City, Utah-based privately held company, which is conducting US clinical trials for its EPN Scan lung cancer screening device, expects to gain FDA approval next year. The device is already marketed in Europe, having received a CE mark in 2013.
The company, also known as Fresh Medical Laboratories, is already “IPO ready,” said the executive, having reported financial statements for three years. The public reporting began as a result of a potential PIPE deal that never occurred in 2012.
Eror said the current fundraising values the company at USD 30m. Proceeds of the fundraising will be used to continue US clinical trials for the device and to hire a sales force for outreach to hospitals and pulmonary specialists.
The current standard for lung cancer diagnosis is CT screening, which is conducted for several years to determine if a lung abnormality is cancerous. ProLungDX says its non-invasive EPN Scan can determine immediately with a 90% accuracy rate whether an abnormality is cancerous so that potentially lifesaving treatment can be undertaken sooner.
The device “replaces months and years of CT follow-up,” the company said in investor materials.
Eror said the company’s end-goal is a dual IPO and sale process in coming years. The executive said ProLungDx is already in talks with major companies that could buy it which he declined to name. But he said large players that could be interested include Medtronic(NYSE:MDT) and Johnson & Johnson (NYSE:JNJ). In addition, the company is “being courted” by NASDAQ for a potential listing.
“We […]

By |2 November 2016|Uncategorized|Comments Off on ProLung Interviewed by National Healthcare Reporter|

ProLungdx Unveils its EPN Scan® at the BIO Investor Forum: Long-Awaited Test for those at Risk of Lung Cancer

Salt Lake City, UT, USA, October 13, 2016 – ProLungdx™ today announced plans to present its leading-edge innovation for patients at risk of lung cancer during the 2016 BIO Investor Forum in San Francisco, California October 18 and 19, 2016.

For the first time in an international biotech investment conference, prospective investors will have the opportunity to review ProLungdx’s Electro Pulmonary Nodule Scan™ or EPN Scan, a device designed to make a difference in time for patients who have the potential for cancer in an indeterminate lung nodule identified by a CT screen or incidental finding. “It is distressing that patients wait months or even years to determine if their lung nodule is cancer,” said Steven Eror, ProLungdx’s CEO. “This waiting time drastically reduces the treatment window for therapy.  The EPN Scan’s purpose is to make a difference in time by reducing or eliminating the wait.”

ProLungdx was selected to present alongside some of the most promising life science companies at the BIO Investor Forum. “The BIO Investor Forum, now in its 15th year, is designed to help biotechnology companies find sources of capital. Attendees have opportunities to learn about the latest investment trends as well as showcase their company to qualified investors,” said Theresa Brady of the BIO Investor Forum.

The EPN Scan is nearing completion of its pivotal work with 14 premier US cancer centers. These represent a consensus of thought leaders seeking to accelerate the assessment of lung cancer risk in pulmonology, radiology, and thoracic surgery. Concern has rapidly increased following this year’s introduction and national reimbursement coverage of the low-dose CT chest screen for lung cancer. The screen has been shown to have a 96% false positive rate for cancer and highlights the […]

By |13 October 2016|Uncategorized|Comments Off on ProLungdx Unveils its EPN Scan® at the BIO Investor Forum: Long-Awaited Test for those at Risk of Lung Cancer|

ProLungdx Showcases its EPN Scan® for Lung Cancer at the White Hat Investors Conference

Salt Lake City, UT, USA, September 7, 2016 – ProLungdx™ today announced plans to present its ground-breaking innovation for lung cancer patients at the AZBIO’s 2016 White Hat Life Science Investors Conference in Phoenix, Arizona September 21 and 22, 2016.

For the first time in an investment opportunity conference, prospective investors will be able to get a glimpse of ProLungdx’s Electro Pulmonary Nodule Scan™ or EPN Scan, a device designed to bridge the gap in the current standard of care between the detection of indeterminate pulmonary nodules and the risk of malignancy.  “It is distressing that patients wait months or even years to determine if their lung nodule is cancer. This waiting time drastically reduces the treatment window for therapy.  The EPN Scan’s purpose is to make a difference in time by reducing or eliminating the wait,” says Steven Eror, ProLungdx’s CEO.

The selection of ProLungdx to present alongside the most innovative life science companies at White Hat 2016 is significant.  It highlights the rapidly accelerating concern following the introduction and reimbursement of the low-dose CT chest screen for lung cancer, which has been shown to have a 96% false positive rate for cancer.  Leading medical experts universally agree that advances in lung cancer management present the largest opportunity to reduce cancer mortality.

“The Rocky Mountain Southwest Region is home to a wide range of exciting life science companies and diagnostics is one of our strongest areas,” shared Joan Koerber-Walker, president and CEO of AZBio and part of the organizing committee for White Hat 2016. “Companies from across the region competed to be selected for one of the 32 presentation slots and were scored and reviewed by a panel of active life science investors to get the […]

By |7 September 2016|Uncategorized|Comments Off on ProLungdx Showcases its EPN Scan® for Lung Cancer at the White Hat Investors Conference|

University of Liverpool Lung Cancer Research

Lung cancer survival rate increases by 73% if caught early
A major lung cancer screening trial, conducted by experts at the University of Liverpool, has found
that patients with a high risk of
developing lung cancer can be identified
with early stage disease and have up to a
73% chance of surviving five years or
more.
The UK Lung Cancer Screening Trial
(UKLS) was undertaken in partnership
with Liverpool Heart & Chest
Hospital, Papworth Hospital and the Royal Brampton & Harefield Hospital with the aim of
highlighting the need for a screening programme to help benefit people who are at risk of developing
lung cancer.
The Chief Investigator of the UKLS trial is Progessor Jogn Field, who is based in the University’s
Institute of Translational Medicine.
Identifying those at risk
Lung cancer kills more people than any other cancer. The number of deaths in 2012 in the UK
was 35,370, making lung cancer the commonest cause of cancer death in the UK for both
men and women.
The main reasons why lung cancer outcomes are so poor, are that approximately 70% of
patients first present to specialist care with incurable advanced disease and current
treatment at this late stage has very little effect on mortality.
However, if a patient’s lung cancer is identified at an early stage, then the clinical outcome is
greatly improved. Individuals with very early stage disease have up to a 73% chance of
surviving for five years or more and over 80% have had surgical interventions. As a result
there is a major national and international focus on CT screening trials.
National screening programme
The results of the UKLS trial provide further evidence for the UK National Screening
Committee (UKNSC) to consider when making a decision whether to implement a national
screening programme in the UK in the future.
Funded by the NIHR Health Technology Assessment Programme the trial was the first and
only lung cancer screening trial to take […]

By |3 June 2016|Uncategorized|Comments Off on University of Liverpool Lung Cancer Research|

ProLungdx Announces Todd Morgan as Chairman of the Board

Salt Lake City, Utah, May 19, 2016 – Fresh Medical Laboratories, Inc, doing business as ProLungdx™, announced today that its board has appointed Todd Morgan as Chairman of the Board of Directors.  Mr. Morgan succeeds Clark Campbell, who served as the Chairman from 2012 to 2016.  Todd Morgan has been a Director since 2014 and begins his role as Chairman while ProLungdx markets its Electro Pulmonary Nodule Scanner (EPN Scan)â in Europe and seeks FDA approval in the US.

“Todd Morgan is an extraordinarily successful entrepreneur. He brings senior management ability with business and banking board experience,” said Steven Eror, President and CEO of ProLungdx.  “His leadership will help guide ProLungdx through our next period of growth and expansion.”

Mr. Morgan is a successful and widely respected businessman.  He began his career with The West Bend Company in the sales department and served as the District Manager.  He started Morgan Industries, an asphalt paving and maintenance business, growing it from one employee to 150 employees with offices in Utah and Arizona, and contracting in seven western states.  Mr. Morgan also started NuRock, a company which manufactures asphalt maintenance products.  He formed MPM Investment Group LP and currently serves as general partner and manager.  Mr. Morgan served on the Board of Directors of America West Bank and is a current member of the Board of Directors of Ellison Ranching Company.

About ProLungdx

ProLungdx is a privately held, US-based medical technology company that develops, manufactures and sells non-invasive medical technology to aid in the early detection and diagnosis of lung cancer.  The EPN Scan is approved for sale in the European Economic Area and is for investigational use only in the US.

For more information, contact:

C. Lindsay McSweeney

801-308-8861

info@prolungdx.com

By |19 May 2016|Uncategorized|Comments Off on ProLungdx Announces Todd Morgan as Chairman of the Board|